Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Arcutis Biotherapeutics Inc. | ZORYVE foam 0.3% | Vitiligo | Phase 2 | Enrollment Initiation | Topical | N/A |
| Arcutis Biotherapeutics Inc. | ZORYVE (roflumilast) Cream 0.05% - (INTEGUMENT-INFANT) | Atopic Dermatitis | sNDA Filing | Data Released | Topical | Immunology |
| Arcutis Biotherapeutics Inc. | ARQ-252 | Chronic Hand Eczema | Phase 2b | Trial Completed | Topical | #N/A |
| Arcutis Biotherapeutics Inc. | Roflumilast Cream (ARQ-151) - (DERMIS-1) | Plaque psoriasis | Phase 3 | Data Released | Topical | Immunology: Anti-TNF |
| Arcutis Biotherapeutics Inc. | ZORYVE foam 0.3% | Hidradenitis suppurativa | Phase 2 | Enrollment Initiation | Topical | #N/A |
| Arcutis Biotherapeutics Inc. | Roflumilast Cream (ARQ-151) - (DERMIS-1) | Plaque psoriasis | Phase 3 | Data Released | Topical | Immunology: Anti-TNF |
| Ardelyx Inc. | Tenapanor - (AMPLIFY) | Hyperphosphatemia - adjunctive therapy to phosphate binders | Phase 3 | Data Released | Oral | N/A |
| Ardelyx Inc. | Tenapanor - (T3MPO-1) | Constipation-predominant irritable bowel syndrome (IBS-C) | Phase 3 | Trial Completed | Oral | Gastroenterology |
